🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

212 results for “Bristol-Myers” Clear

  1. FLUTICASONE , Dupilumab, SALBUTAMOL , BUDESONIDE , MONTELUKAST , Matched placebo for test (dupilumab low dose), Matched placebo for test (dupilumab high dose), BECLOMETASONE , Dupilumab, SALMETEROL AND FLUTICASONE

    Sanofi Pharma Bristol-Myers Squibb

    Respiratory tract diseases - Wheezing, Asthma

    phase 3 small molecule active

    1 trial

  2. Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.

    Sanofi Pharma Bristol-Myers Squibb

    Fabry’s disease

    phase 3 small molecule active

    1 trial

  3. Frexalimab

    Sanofi Pharma Bristol-Myers Squibb

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  4. GEMCI-cell® 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Gemcitabine 1 g Powder for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Carbomedac® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusio

    Bristol-Myers Squibb / Pfizer EEIG

    Untreated Unresectable or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  5. GEMCITABINE, Mrtx1719 matching placebo, PACLITAXEL ALBUMIN-BOUND, MRTX1719

    Bristol-Myers Squibb / Pfizer EEIG

    Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  6. GEMCITABINE, PEGFILGRASTIM, PACLITAXEL ALBUMIN-BOUND, BL-B01D1, CAPECITABINE, CARBOPLATIN, PACLITAXEL, CAPECITABINE

    Bristol-Myers Squibb / Pfizer EEIG

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  7. Humira 40 mg solution for injection in pre-filled syringe, Abatacept

    Bristol-Myers Squibb / Pfizer EEIG

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  8. Imnovid 3 mg hard capsules, Isatuximab, Dexamethason 4 mg JENAPHARM®, JAMP Pomalidomide, JAMP Pomalidomide, Isatuximab, Imnovid 4 mg hard capsules, JAMP Pomalidomide, MONTELUKAST , Pomalidomide Adalvo 4 mg hard capsules, JAMP Pomalidomide, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Imnovid 1 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, DEXAMETHASONE, Imnovid 1 mg hard capsules, Isatuximab, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Dexamethason

    Sanofi Pharma Bristol-Myers Squibb

    Cancer - Plasma cell myeloma recurrent

    phase 3 small molecule active

    1 trial

  9. Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, Ipilimumab, Sutent 12.5 mg hard capsules, Sutent 12.5 mg hard capsules

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or Metastatic Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  10. Itepekimab, Matched Placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  11. Itepekimab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  12. Itepekimab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  13. KarX-EC, KarX-EC, KarX-EC matching placebo, KarXT, KarXT, KarX-EC, KarX-EC, KarXT matching placebo, KarXT, KarXT

    Bristol-Myers Squibb / Pfizer EEIG

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  14. KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC, KarXT, KarXT

    Bristol-Myers Squibb / Pfizer EEIG

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  15. KarX-EC, KarXT, KarX-EC matching placebo, KarX-EC, KarXT, KarXT, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb / Pfizer EEIG

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  16. KarXT, KarX-EC matching Placebo, KarX-EC, KarXT matching Placebo, KarXT, KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT

    Bristol-Myers Squibb / Pfizer EEIG

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  17. KarXT, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC matching Placebo, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb / Pfizer EEIG

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  18. KarXT, KarXT Matching Placebo, KarXT, KarXT

    Bristol-Myers Squibb / Pfizer EEIG

    Schizophrenia

    phase 3 small molecule active

    1 trial

  19. KarXT, KarXT, KarXT, KarXT

    Bristol-Myers Squibb / Pfizer EEIG

    Mania or Mania with Mixed Features in Bipolar-I Disorder

    phase 3 small molecule active

    1 trial

  20. KarXT, KarXT, KarXT, KarXT Matching Placebo

    Bristol-Myers Squibb / Pfizer EEIG

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  21. KarXT, KarXT, KarXT, KarXT, KarXT Matching Placebo

    Bristol-Myers Squibb / Pfizer EEIG

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  22. KarXT, KarXT, KarXT, KarXT, KarXT, Placebo

    Bristol-Myers Squibb / Pfizer EEIG

    Psychosis Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  23. KarXT, KarXT, KarXT, Karxt Matching Placebo

    Bristol-Myers Squibb / Pfizer EEIG

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  24. LORATADINE , FEXOFENADINE , Dupilumab, Matched placebo to test

    Sanofi Pharma Bristol-Myers Squibb

    Pruritus

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources